Researchers at Aarhus University demonstrated a prime-editing approach that corrects genetic defects in a patient’s own blood stem cells in a study focused on GATA2 deficiency. The report says the editing increased the fraction of normally functioning gene copies in stem cells from roughly 50% to 70%, alongside improvements in the relevant protein function. The key translational point is that prime editing avoids full DNA double-strand breaks used in traditional CRISPR workflows, potentially reducing certain kinds of unintended genomic changes. The investigators positioned the approach as closer to treating underlying causes rather than managing downstream consequences. While the work is framed as a feasibility step rather than a ready-to-use therapy, it provides proof that repairing only part of the gene-corrected population may be sufficient to improve cell function. The report notes the platform is not yet ready for clinical use in patients, but it moves prime editing closer to autologous stem-cell strategies for immune deficiencies.